NCT00485615已完成2 期
An Open-label, Pilot Study Evaluating the Efficacy of Enteric-coated Eicosapentaenoic Acid (o3mega+Joy) in the Treatment of Social Phobia
START Clinic for Mood and Anxiety Disorders1 个研究点 分布在 1 个国家目标入组 8 人开始时间: 2008年10月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 8
- 试验地点
- 1
- 主要终点
- Changes in intensity of the vasodilatory response to 10 mM topical m-N over 16 weeks.
研究概览
简要总结
The primary objective is to evaluate the efficacy of an enteric-coated, eicosapentaenoic acid-concentrated fish oil in the treatment of social phobia. A secondary objective is to determine if treatment outcome is related to plasma phospholipid essential fatty acid status, niacin skin flush and measures of lipid/protein peroxidation.
详细描述
Subjects meeting criteria for Social Anxiety Disorder, will receive enteric-coated, eicosapentaenoic acid-concentrated fish oil (O3mega+Joy) for 12 weeks of treatment for social phobia. A secondary objective is to determine if treatment outcome is related to changes in plasma phospholipid essential fatty acid status, niacin skin flush and measures of lipid/protein change.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Eligible for this trial are patients who meet all of the following criteria:
- •The patient has provided signed informed consent.
- •Outpatients aged 18-65 (extremes included).
- •Patients with a primary diagnosis of Social Phobia according to DSM IV (300.23) criteria (diagnosis to be made using the Mini International Neuropsychiatric Interview (MINI)).
- •On the basis of a physical examination, medical history and basic laboratory screening, the patient is, in the investigators opinion, in a suitable condition.
- •Willing and able to attend study appointments in the correct time windows.
排除标准
- •Patients meeting one or more of the following criteria cannot be selected for inclusion:
- •Any other axis I diagnosis that was a primary disorder in the previous six months.
- •Continuation or commencement of formal psychotherapy.
- •Alcohol or drug abuse as defined in the DSM IV within the last six months.
- •Mania or hypomania as defined in the DSM IV.
- •Current use of or commencement of antidepressant and anxiolytic medications.
- •Patients who have been on an antidepressant or other anxiolytic prior to the study, will have discontinued it more than two weeks prior to entry into the study. Those who have been on fluoxetine, will have been off of it for at least 5 weeks
- •Patients who have been on an herbal or alternative treatment judged to be potentially anxiolytic or with psychobiological activity, will have terminated usage of the agent more than two weeks prior to entering the study..
- •Any psychotic disorder.
- •Eating disorders as defined in the DSM IV.
- •Mental retardation or other cognitive disorder.
- •Clinical interpretation of apparent suicide risk.
- •Previous treatment efforts using 4000mg or more of fish oil daily.
- •Current use of or commencement of essential fatty acid supplementation.
- •Significant alterations from Standard North American Diet ie any special diets either restrictive of or inclusive of typical carbohydrate, protein and fat intake.
- •Known sensitivity to fish oil or fish products.
- •Any disorder of clotting or current use of warfarin.
- •Laboratory values at screening or in medical history that may be considered through clinical interpretation to be significant.
- •Diseases which could, through clinical interpretation, interfere with the assessments of safety, tolerability and efficacy.
- •Serious illness: Liver or renal insufficiency, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurological, infectious, neoplastic or metabolic disturbance.
- •The patient is, in the opinion of the investigator, unlikely to be able to comply with the clinical trial protocol, or is unsuitable for any other reasons.
- •Pregnant and breastfeeding females
- •Females of childbearing years who do not use contraception.
研究组 & 干预措施
1
Experimental
OMEGA 3
干预措施: Omega 3 Joy enteric coated concentrated fish oil (Drug)
结局指标
主要结局
Changes in intensity of the vasodilatory response to 10 mM topical m-N over 16 weeks.
时间窗: Pre treatment - Post treatment
次要结局
- SPIN, SIAS,SPS, ASI, BDI, BAI, SDS, Euroquol, SF 36, BI/BAS, BTSQ, BPS, Niacin Flushing Challenge(Post treatment - Pre Treatment)
研究者
Dr. Martin A. Katzman
Principal Investigator
START Clinic for Mood and Anxiety Disorders
研究点 (1)
Loading locations...
相似试验
终止
2 期
MMV390048 POC in Patients With P. Vivax and P. Falciparum MalariaMalariaNCT02880241Medicines for Malaria Venture8
已完成
1 期
Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic DisordersDermatitis, AtopicHay FeverNCT00189917Bavarian Nordic60
终止
2 期
A Study to Evaluate the Efficacy, Safety, and Tolerability of MYK-224 in Participants With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, HypertrophicNCT05556343Bristol-Myers Squibb18
已完成
1 期
Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)Non-Small-Cell Lung CancerNCT02835690Merck Sharp & Dohme LLC44
已完成
2 期
An Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Edge)AcromegalyNCT03789656Crinetics Pharmaceuticals Inc.47